TCRT (Alaunos Therapeutics) Tariff Resilience Score: 6/10 (As of Jul. 06, 2026)


TCRT Alaunos Therapeutics Inc TCRT
28 GF Score
Price $2.08
GF Value $0.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alaunos Therapeutics Tariff Resilience Score?

Alaunos Therapeutics TCRT -4.37% 28 Tariff Resilience Score is 6 as of Jul. 06, 2026. GuruFocus rates TCRT with a GF Score™ of 28/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,369 Biotechnology companies, Alaunos Therapeutics ranks better than 75.89% on this metric.

Alaunos Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Alaunos Therapeutics has Biotech firm with some exposure to tariffs on imported research materials. Historical impact minimal due to niche market. Mitigation through strategic partnerships and potential for domestic sourcing.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Alaunos Therapeutics might have Average Resilient.

Alaunos Therapeutics  (NAS:TCRT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Alaunos Therapeutics Tariff Resilience Score Related Terms

TCRT vs DRMA, MBIO, ELAB: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Alaunos Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alaunos Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's Tariff Resilience Score falls into.


TCRT
28GF Score
Alaunos Therapeutics Inc TCRT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Alaunos Therapeutics (TCRT) has a Tariff Resilience Score of 6 as of Jul. 06, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Alaunos Therapeutics ranks #330 out of 1369 companies in the Biotechnology industry, placing it in the top 24.1%.
Is Alaunos Therapeutics' Tariff Resilience Score too high?
Alaunos Therapeutics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Alaunos Therapeutics' value of 6 is 50% above this industry median. Based on the distribution chart, Alaunos Therapeutics ranks #330 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alaunos Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alaunos Therapeutics' Tariff Resilience Score compare to DRMA and MBIO?
According to the Biotechnology industry distribution chart, Alaunos Therapeutics ranks #330 out of 1369 companies for Tariff Resilience Score. This places Alaunos Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Alaunos Therapeutics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alaunos Therapeutics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alaunos Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alaunos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Alaunos Therapeutics (TCRT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.08 — trading 205.9% above its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Alaunos Therapeutics' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Alaunos Therapeutics (TCRT), the current Tariff Resilience Score is 6 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alaunos Therapeutics (TCRT) Overvalued in 2026?

Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued. The current stock price of $2.08 is trading 205.9% above its estimated GF Value™ of $0.68. GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.

Key valuation signals for TCRT:

  • Tariff Resilience Score: 6
  • GF Value™: $0.68 vs. price of $2.08 (205.9% above fair value)
  • GF Score™: 28/100 with 4 warning signs
  • Industry Position: 50% above the Biotechnology median (#330 of 1369)

No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alaunos Therapeutics Business Description

Address 501 East Las Olas Boulevard, Suite 300, Fort Lauderdale, FL, USA, 33301
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
28GF Score

Get the complete analysis for TCRT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price
$0.68
GF Value